H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Eton Pharmaceuticals today and set a price target of $35.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Swayampakula Ramakanth has given his Buy rating due to a combination of factors that indicate a promising growth trajectory for Eton Pharmaceuticals. The company has projected significant revenue growth, with expectations to nearly double their product revenue in 2025 compared to 2024. This growth is supported by their current commercial portfolio, which is anticipated to reach peak sales of over $125 million, and potential label expansions for key products like Khindivi and Increlex, which could add substantial additional revenue.
Furthermore, Eton’s development pipeline, including five clinical candidates, is expected to contribute significantly to future sales, with a forecasted total revenue increase to $476 million by 2034. The first half of 2026 is anticipated to be catalyst-rich, with several potential value-creating events such as FDA decisions and clinical data releases. The valuation of Eton’s shares, supported by a risk-adjusted net present value analysis, aligns with a 12-month price target of $35, reinforcing the Buy rating despite inherent risks like clinical and commercial challenges.
Ramakanth covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics, Nanobiotix, and Evaxion Biotech. According to TipRanks, Ramakanth has an average return of 19.6% and a 46.31% success rate on recommended stocks.
In another report released on December 5, Craig-Hallum also reiterated a Buy rating on the stock with a $29.00 price target.